Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05312970 · ClinicalTrials.gov registry record · Phase 4
Varithena Versus Endothermal Ablation of the Great Saphenous Vein (VERITAS)
A Phase 4 study, sponsored by Boston Scientific Corporation.
- Terminated
- Registry status
- Phase 4
- Development phase
- 43
- Enrollment target
NCT05312970: Clinical Trial Phase 4 study, sponsored by Boston Scientific Corporation.
NCT05312970 is a Phase 4 study that was terminated before completion, run by Boston Scientific Corporation. The registered enrollment target is 43 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05312970, a Phase 4 study, was terminated before completion, sponsored by Boston Scientific Corporation.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 43 participants
- Enrollment target
Study Summary
The purpose of this study is to observe insights into the benefits of Varithena compared to Endothermal Ablation (ETA) in the treatment of the great saphenous vein.
Primary Outcome
Mean change in points of total score on Varicose Veins Symptoms Questionnaire (VVSymQ) between baseline and 3-month post treatment. VVSymQ scores range from 0 to 25, where 0 represents no symptoms and 25 represents all 5 symptoms experienced all of the time.
Interventions
- DRUG Varithena®
- DEVICE FDA-approved Endothermal Ablation (ETA) systems
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2023-02-10 |
| Est. Completion | 2024-04-04 |
| Phase | Phase 4 |
Why NCT05312970 stopped before completion
NCT05312970 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which Varithena® is the first listed.
NCT05312970 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05312970 about?
NCT05312970 is a clinical study titled "Varithena Versus Endothermal Ablation of the Great Saphenous Vein (VERITAS)". The purpose of this study is to observe insights into the benefits of Varithena compared to Endothermal Ablation (ETA) in the treatment of the great saphenous vein.
What is the current status of trial NCT05312970?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 43 participants. The study started on 2023-02-10. Estimated completion is 2024-04-04.
What interventions are being tested in trial NCT05312970?
The interventions under investigation include: Varithena® (DRUG), FDA-approved Endothermal Ablation (ETA) systems (DEVICE).
Who is sponsoring clinical trial NCT05312970?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05312970's enrollment target sits among peer trials
43 1371st of 2000 higher than 621 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI